The future of CRISPR in Mycobacterium tuberculosis infection

J Biomed Sci. 2023 May 27;30(1):34. doi: 10.1186/s12929-023-00932-4.

Abstract

Clustered Regularly Interspaced Short Palindromic repeats (CRISPR)-Cas systems rapidly raised from a bacterial genetic curiosity to the most popular tool for genetic modifications which revolutionized the study of microbial physiology. Due to the highly conserved nature of the CRISPR locus in Mycobacterium tuberculosis, the etiological agent of one of the deadliest infectious diseases globally, initially, little attention was paid to its CRISPR locus, other than as a phylogenetic marker. Recent research shows that M. tuberculosis has a partially functional Type III CRISPR, which provides a defense mechanism against foreign genetic elements mediated by the ancillary RNAse Csm6. With the advent of CRISPR-Cas based gene edition technologies, our possibilities to explore the biology of M. tuberculosis and its interaction with the host immune system are boosted. CRISPR-based diagnostic methods can lower the detection threshold to femtomolar levels, which could contribute to the diagnosis of the still elusive paucibacillary and extrapulmonary tuberculosis cases. In addition, one-pot and point-of-care tests are under development, and future challenges are discussed. We present in this literature review the potential and actual impact of CRISPR-Cas research on human tuberculosis understanding and management. Altogether, the CRISPR-revolution will revitalize the fight against tuberculosis with more research and technological developments.

Keywords: CRISPR-Cas; CRISPRi; Diagnostic methods; Functional genomics; MTBC; Mycobacterium tuberculosis; Spoligotyping.

Publication types

  • Review

MeSH terms

  • CRISPR-Cas Systems
  • Genes, Bacterial
  • Humans
  • Mycobacterium tuberculosis* / genetics
  • Phylogeny
  • Tuberculosis* / diagnosis
  • Tuberculosis* / genetics